Generic antivirals a booster dose forHepatitis C
business Updated: Dec 24, 2015 19:12 IST
New generic oral antiviral drugs for Hepatitis C has come as a major relief for almost 12 to 18 million Indians affected by the disease.
The prices are about one hundredth of that in developed countries like the US and Japan.
While one tablet of sofosbuvir costs around Rs 30,000 in Japan, it comes for around Rs. 350 in India; For daclatasvir, the difference is around Rs.10,000 and Rs. 135, and for the combination drug of sofosbuvir and ledipasvir, it is Rs.40,000 and Rs.500. The prices are even higher in markets like the US, according to doctors of both countries that HT talked to.
Sofosbuvir, daclatasvir, and ledipasvir are generic names of the medicines for treatment of the disease.
Hepatitis C is caused by virus and can lead to cirrhosis, liver cancer and liver failure.
“Till date the treatment of Hepatitis C revolved around weekly interferon injections, notorious for severe and disabling side effects. Now, new oral antiviral drugs are available in India at an affordable cost with almost negligible side effects and high cure rates,” according to the Asia-Pacific Association for Study of the Liver (APASL).
“It is like saying the Crocin for Hepatitis C is here”, said a doctor at the Institute of Liver and Biliary Science.
“The low price would also attract many foreigners to come and get treatment here,” said Shiv K Sarin, chairman, APASL. The new drugs have a success rate of more than 95%, and the association was pushing the government to make the treatment free, as in the case of TB, he added.
Sofosbuvir is sold by Gilead Sciences Inc under the brand name of Sovaldi. The Indian Patent office had, in January 2015, rejected its patent application citing that the drug was not inventive enough compared to a previous formulation. It paved the way for Indian generic drug manufacturers to produce a much cheaper drug, which in the US cost around $1,000-a-pill.
Natco and Hetero got the Drugs Controller General of India approval to launch ledipasvir + sofosbuvir combination and daclatasvir in the second week of December, while Strides Shasun Ltd received the approval to make sofosbuvir on Monday.